Indications for: DEPO-PROVERA CI
Limitations of Use:
Not recommended as a long-term (eg, >2yrs) birth control method unless other options are considered inadequate.
Give by deep IM inj in the gluteal or deltoid muscle; rotate inj sites. 150mg every 3 months (13 weeks). Give 1st dose within 5 days of onset of normal menses (see full labeling for postpartum).
Pre-menarche: not applicable.
DEPO-PROVERA CI Contraindications:
Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.
Loss of bone mineral density.
DEPO-PROVERA CI Warnings/Precautions:
May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Monitor conditions aggravated by fluid retention. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.
DEPO-PROVERA CI Classification:
DEPO-PROVERA CI Interactions:
May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.
Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.
Vials—1, 25; Prefilled syringe (1mL)—1 (w. needles); SubQ (prefilled syringe)—1 (w. needle)